China Pharma Holdings, Inc. (NYSE:CPHI) tinted gains of +1.68% (0 points) to US$0.25. The volume of 0.09 Million shares climbed down over an trading activity of 320.02 Million shares. EPS ratio determined by looking at last 12 month figures is -0.43. Over the same time span, the stock marked US$1.45 as its best level and the lowest price reached was US$0.15. The corporation has a market cap of US$11.22 Million.
China Pharma Holdings, Inc. (NYSE:CPHI)’s earnings per share has been growing at a -43.9 percent rate over the past 5 year when average revenue increase was noted as -24.7 percent. The return on equity ratio or ROE stands at -36.9 percent while most common profitability ratio return on investment (ROI) was -35.5 percent. The company’s institutional ownership is monitored at 6.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 20.7 percent gross margin.
TechTarget, Inc. (NASDAQ:TTGT) is worth US$778.62 Million and has recently risen 1.68% to US$28.5. The latest exchange of 0.38 Million shares is below its average trading activity of 290.12 Million shares. The day began at US$28.39 but the price moved to US$28.39 at one point during the trading and finally capitulating to a session high of US$28.5. The stock tapped a 52-week high of US$29.53 while the mean 12-month price target for the shares is US$23.75.
Currently, the stock carries a price to earnings ratio of 94.37, a price to book ratio of 6.39, and a price to sales ratio of 6.93. For the past 5 years, the company’s revenue has grown 1.7%, while the company’s earnings per share has grown 18.2%. With an institutional ownership near 57.4%, it carries an earnings per share ratio of 0.3.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.25.